Registration successful
Account activated – pending validation.
Your account has been activated successfully, but we still need to validate you as a healthcare professional. We’ll send you an email with the result of the validation process in the next [five] days.
In the meantime, you can enjoy access to all the latest news, events and resources on our website
WEBINARS
Explore our range of recorded webinars from international experts in the field of infectious disease.
DOVATO | CLOSE THE GAP
HIGH BARRIER TO RESISTANCE
Dovato (Dolutegravir/lamivudine) | Abbreviated Prescribing Information
POM A. Marketing Authorisation Number: EU/1/19/1370/001-004. Further information available from GlaxoSmithKline, 12 Riverwalk, Citywest, Business Campus, Dublin 24. Tel: 01-4955000.
Adverse events should be reported directly to the Health Products Regulatory Authority (HPRA) on their website: www.hpra.ie. Adverse events should also be reported to GlaxoSmithKline on 1800 244 255.
PM-IE-DLL-WCNT-240009 | Date of Preparation: October 2024
PASO DOBLE STUDY
DR. ESTEBAN MARTINEZ
Dovato (dolutegravir/lamivudine) | Abbreviated Prescribing Information
POM A. Marketing Authorisation Number: EU/1/19/1370/001-004. Further information available from GlaxoSmithKline, 12 Riverwalk, Citywest, Business Campus, Dublin 24. Tel: 01-4955000.
Adverse events should be reported directly to the Health Products Regulatory Authority (HPRA) on their website: www.hpra.ie. Adverse events should also be reported to GlaxoSmithKline on 1800 244 255.
PM-IE-DLL-WCNT-240008 | Date of Preparation: September 2024
A 7 Chapter Webinar: Dr Jan Borch on Long-Acting Injectables
Vocabria
Overview of LAI studies in ARV therapy
Chapter 1 of 7
CVF rates in LAI studies
Chapter 2 of 7
Vocabria & Rekambys Patient Case Study 1
Chapter 3 of 7
Vocabria & Rekambys Patient Case Study 2
Chapter 4 of 7
Vocabria & Rekambys Patient Case Study 3
Chapter 5 of 7
Patients who may benefit from LAI
Chapter 6 of 7
Safety Information for Vocabria and Rekambys
Chapter 7 of 7
POM A. Marketing Authorisation Number: EU/1/20/1481/003. Further information available from GlaxoSmithKline, 12 Riverwalk, Citywest, Business Campus, Dublin 24. Tel: 01-4955000.
Adverse events should be reported directly to the Health Products Regulatory Authority (HPRA) on their website: www.hpra.ie. Adverse events should also be reported to GlaxoSmithKline on 1800 244 255.
PM-IE-CBR-WCNT-240003 | Date of Preparation: June 2024
A Three Chapter Webinar with Professor Guaraldi on The Art of Individualised Care: Making HIV a Smaller Part of Our Patients’ Lives
Frailty in HIV Patients
Chapter 1 of 3
Ageing Healthy with HIV
Chapter 2 of 3
Benefits of Patient Reported Outcomes
Chapter 3 of 3
POM A. Marketing Authorisation Number: EU/1/19/1370/001-004. Further information available from GlaxoSmithKline, 12 Riverwalk, Citywest, Business Campus, Dublin 24. Tel: 01-4955000.
Adverse events should be reported directly to the Health Products Regulatory Authority (HPRA) on their website: www.hpra.ie. Adverse events should also be reported to GlaxoSmithKline on 1800 244 255.
PM-IE-DLL-WCNT-240001 | Date of Preparation: June 2024
Adverse events should be reported directly to the Health Products Regulatory Authority (HPRA) on their website: www.hpra.ie. Adverse events should also be reported to GlaxoSmithKline on 1800 244 255.
Healthcare professionals are asked to report any suspected adverse reactions.
REKAMBYS (rilpivirine long acting), including the trademark, is owned by the Janssen Pharmaceutical Companies and used under licence by the ViiV Healthcare group of companies.
All other trademarks are owned by the ViiV Healthcare group, or its licensor.
©2024 GSK group of companies. All rights reserved.
Date of preparation: June 2024 | PM-IE-HVX-WCNT-240001
